Loading
The World Health Organization's cytopathology reporting systems give each organ a fixed set of report categories for needle and brush samples, each with an estimated risk of cancer and a suggested next step.
The International Academy of Cytology, the International Agency for Research on Cancer and the WHO are writing international systems for reporting cytopathology of the lung, pancreas and biliary tract, lymph nodes, soft tissue, liver, breast, and kidney and adrenal gland, linked to the fifth edition WHO Classification of Tumours (Field and colleagues, Cancer Cytopathology 2023). The lung and pancreaticobiliary systems were published first. Each defines categories and terminology, an estimated risk of malignancy per category as far as the literature allows, and a diagnostic management algorithm, written to work in low- and middle-income settings too.
Central tumours arise in the large airways, peripheral ones in the alveoli; both drain to hilar then mediastinal nodes, and the pleural lining is a separate cancer site.
Same organ: Mediastinal germ cell tumour, Pleuropulmonary blastoma (types I, Ir, II and III), Type A and type AB thymoma, Type B1 and type B2 thymoma, Type B3 thymoma, Micronodular thymoma with lymphoid stroma, Adenocarcinoma of the lung, Squamous cell carcinoma of the lung, Large cell carcinoma of the lung, Sarcomatoid carcinoma of the lung, Adenosquamous carcinoma of the lung, Invasive mucinous adenocarcinoma of the lung, Adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung, Basaloid squamous cell carcinoma of the lung, Lymphoepithelial carcinoma of the lung, Pulmonary blastoma (adult), Non-small-cell lung cancer, Small-cell lung cancer, Mesothelioma, Pleural mesothelioma, Thymoma and thymic carcinoma, Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours), Inflammatory myofibroblastic tumour (IMT), EGFR-mutated non-small-cell lung cancer, ALK-positive non-small-cell lung cancer, KRAS G12C-mutant non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer, MET exon 14 and MET-amplified non-small-cell lung cancer, RET fusion-positive non-small-cell lung cancer, BRAF V600E-mutant non-small-cell lung cancer, HER2-mutant non-small-cell lung cancer, NTRK fusion-positive non-small-cell lung cancer, PD-L1-high non-small-cell lung cancer without a driver mutation, Resectable stage I to III non-small-cell lung cancer, Unresectable stage III non-small-cell lung cancer, Limited-stage small-cell lung cancer, Extensive-stage small-cell lung cancer, Lung neuroendocrine tumours (typical and atypical carcinoid), Large cell neuroendocrine carcinoma of the lung, Thymoma (WHO types A, AB, B1, B2 and B3), Thymic carcinoma
Showing the organ this term concerns: Lung cancer (all types).
Shares Milan System for Reporting Salivary Gland Cytopathology, Yokohama System for Reporting Breast Fine-Needle Aspiration Cytopathology, Sydney System for lymph node fine-needle aspiration cytopathology.
Shares International System for Reporting Serous Fluid Cytopathology, Lung cancer (all types).
Shares International System for Reporting Serous Fluid Cytopathology, Lung cancer (all types).
Shares Milan System for Reporting Salivary Gland Cytopathology, Bethesda category (thyroid cytology).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/